Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer
Lay Description
This phase II trial studies how well atezolizumab works in treating patients with non-muscle invasive bladder cancer that has come back (recurrent) and has not responded to treatment (refractory) with Bacillus Calmette-Guerin (BCG). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Category
- Cancers and Other Neoplasms
- Urinary Tract and Kidney
- Urinary Bladder
- IRB Number
- 20180230HU
- NCT Number
- NCT02844816
- Open to Enrollment
- Yes
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
Exclusion Criteria
Study Design
Arm Groups
Study Contact
Regulatory Point of Contact
Frances Crawford
(210) 450-5037
crawfordf1@uthscsa.edu
Regulatory Point of Contact
Sonia Creighton
(210) 450-1366
creighton@uthscsa.edu
Regulatory Point of Contact
Myrna Montenegro
(210) 450-5954
montenegro@uthscsa.edu
Regulatory Point of Contact
Chethan Ramamurthy
(210) 450-1667
ramamurthyc@uthscsa.edu
Regulatory Point of Contact
Mailbox Ctrc Regulatory Affairs
regaffapp@uthscsa.edu
Regulatory Point of Contact
Regulatory Staff
regaffstaff@uthscsa.edu
Regulatory Point of Contact
Kathleen Rodriguez
(210) 450-1365
rodriguezk3@uthscsa.edu
Regulatory Point of Contact
Benjamin Schleif
(210) 450-1366
schleifb@uthscsa.edu
Regulatory Point of Contact
Morgan Seekatz
(210) 450-1133
seekatz@uthscsa.edu
Principal Investigator
Chethan Ramamurthy